scnm1 Antibody

What is SCNM1 and what is its primary function in cellular processes?

SCNM1 (Sodium Channel Modifier 1) is a 230 amino acid protein characterized by a C2H2 zinc finger domain at the N-terminal and a C-terminal acidic domain. It functions as a splicing factor, particularly in the recognition of non-consensus splice donor sites. SCNM1 was originally identified as a modifier gene that influences disease severity through a trans-effect on splicing of disease gene transcripts. Recent research has revealed that SCNM1 is a component of the human minor spliceosome, essential for the splicing of U12 intron-containing genes . Its nuclear localization enables it to influence sodium channel-related protein expression, affecting cellular excitability and signaling pathways .

What criteria should researchers consider when selecting an SCNM1 antibody for their experiments?

When selecting an SCNM1 antibody, researchers should consider:

• Specificity: Verify that the antibody has been validated against SCNM1 in your species of interest (human, mouse, rat)

• Applications compatibility: Ensure the antibody is validated for your intended application (WB, IP, IF, ELISA)

• Epitope recognition: Consider which domain of SCNM1 the antibody targets and whether this is relevant to your research question

• Validation data: Review published validation data showing specificity through techniques like western blotting with positive and negative controls

• Format requirements: Determine if you need unconjugated antibody or conjugated versions (HRP, PE, FITC, Alexa Fluor)

• Clonality: Decide between monoclonal (for consistency) or polyclonal (potentially higher sensitivity) based on your experimental needs

How is SCNM1 protein structure related to its function in splicing?

SCNM1's structure consists of a C2H2 zinc finger domain at the N-terminal and a C-terminal acidic domain, both crucial for its splicing function. The zinc finger domain likely facilitates RNA binding, while the acidic C-terminal domain is essential for protein-protein interactions. Research has demonstrated that SCNM1 interacts with the spliceosome protein U1-70K and is co-localized with U1-70K in nuclear speckles in mammalian cells . The C-terminal acidic domain is particularly important for interaction with LUC7L2, a mammalian homolog of a yeast protein involved in recognition of non-consensus splice donor sites. This interaction is disrupted in the disease susceptibility variant found in mouse strain C57BL/6J, where the C-terminal domain is truncated (R187X) . The structural elements of SCNM1 together enable its function in recognizing weak splice donor sites and facilitating correct splicing .

What are the optimal conditions for using SCNM1 antibodies in co-immunoprecipitation experiments to investigate spliceosome interactions?

For optimal co-immunoprecipitation of SCNM1 with spliceosome components:

Protocol Considerations:

• Lysis buffer: Use a gentle buffer that preserves nuclear protein complexes (e.g., 20 mM HEPES pH 7.9, 150 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5% NP-40) supplemented with protease inhibitors and phosphatase inhibitors

• Nuclear extraction: Since SCNM1 is predominantly nuclear, optimize nuclear extraction protocols prior to IP

• Cross-linking: Consider mild cross-linking with formaldehyde (0.1-0.3%) to stabilize transient protein-protein interactions

• Antibody ratio: Use 2-5 μg of SCNM1 antibody per 500 μg of nuclear extract

• Incubation conditions: Overnight incubation at 4°C with gentle rotation

Validation Controls:

• Include IgG-matched negative control

• Use cells with knocked-down or knocked-out SCNM1 as negative controls

• Include DNase/RNase treatment controls to distinguish direct protein interactions from nucleic acid-mediated associations

• Validate interactions with known partners (e.g., U1-70K, spliceosomal core Smith (Sm) proteins, LUC7L2)

How can contradictory results in SCNM1 antibody staining patterns be resolved across different cell types?

When faced with contradictory SCNM1 antibody staining patterns across different cell types:

• Validation with multiple antibodies:

  • Use antibodies from different vendors targeting different epitopes

  • Compare monoclonal and polyclonal antibodies to identify consistent patterns

• Peptide competition assay:

  • Pre-incubate antibody with the immunizing peptide to confirm specificity

  • The specific signal should be abolished or significantly reduced

• Genetic validation:

  • Use SCNM1 knockout/knockdown cells as negative controls

  • Employ SCNM1 overexpression systems as positive controls

• Cell type-specific expression analysis:

  • Compare SCNM1 expression levels by qRT-PCR and Western blot across cell types

  • Assess alternative splicing of SCNM1 in different cell types which might affect epitope availability

• Co-localization studies:

  • Confirm nuclear localization with nuclear markers

  • Verify co-localization with known spliceosomal markers like U1-70K

• Fixation and permeabilization optimization:

  • Test multiple fixation methods (PFA, methanol, acetone)

  • Optimize permeabilization conditions for nuclear proteins

• Documentation and reporting:

  • Maintain detailed records of antibody lots, dilutions, and protocols

  • Report all optimization steps in publications to advance methodological consistency

What considerations are important when designing a minigene splicing assay to evaluate SCNM1 function?

When designing a minigene splicing assay to evaluate SCNM1 function:

Design Components:

• Construct selection: Include exons and introns of interest, particularly those containing non-consensus splice sites or U12-type introns

• Reference gene: Consider using the SCNM1 wild-type minigene spanning from intron 1 to intron 5 as described in previous studies

• Mutations: Introduce specific mutations in splice sites to test SCNM1's ability to recognize and process non-consensus sites

• Vector selection: Use an appropriate exon trapping vector like pSPL3 with EcoRI/XhoI restriction sites

Experimental Design:

• Cell models: Test in multiple cell lines with varying endogenous SCNM1 levels

• Transfection controls: Include appropriate controls for transfection efficiency

• SCNM1 modulation: Perform parallel experiments with SCNM1 overexpression, knockdown, and rescue

• RNA extraction timing: Optimize time points for RNA collection after transfection

Analysis Methods:

• RT-PCR: Design primers spanning the vector exons to detect all splicing events

• Quantification: Use both gel analysis and real-time PCR to quantify splicing efficiency

• Sequencing validation: Confirm splicing products by Sanger sequencing

• Controls: Include known SCNM1 targets as positive controls (e.g., the Scn8a mutant donor site)

Validation Approaches:

• Compare wild-type SCNM1 vs. mutant versions (e.g., R187X variant found in C57BL/6J mice)

• Test reporter constructs in cells derived from different genetic backgrounds

• Validate findings in vivo using appropriate mouse models

How does SCNM1 dysfunction contribute to orofaciodigital syndrome, and what experimental approaches best model this disease?

SCNM1 dysfunction contributes to orofaciodigital syndrome (OFD) through disruption of minor intron (U12) splicing, which affects genes critical for cilia function and development. Recent research has identified bi-allelic loss-of-function variants in SCNM1 as a cause of OFD .

Disease Mechanism:

• Loss of SCNM1 function impairs the processing of U12 intron-containing genes

• Defective splicing particularly affects genes like TMEM107 and FAM92A that encode primary cilia and basal body proteins

• This leads to abnormally elongated cilia and altered Hedgehog (Hh) signaling

• The ciliary defects result in the characteristic OFD phenotype (anomalies of the oral cavity, face, and digits)

Optimal Experimental Models:

• Patient-derived fibroblasts:

  • Directly assess splicing defects and cilia abnormalities in cells from affected individuals

  • Compare transcriptome profiles to identify affected U12 intron-containing genes

• CRISPR-engineered cell lines:

  • Create SCNM1 knockout hTERT RPE-1 cells

  • Generate cell lines with specific patient mutations

  • Perform rescue experiments by reintroducing wild-type SCNM1 via retroviral delivery

• siRNA knockdown models:

  • Use transient knockdown to assess acute effects on splicing and cilia

  • Compare with stable knockout models to distinguish between acute and compensated phenotypes

• Mouse models:

  • Use existing Scnm1 mutant mouse models like the targeted deletion of exons 3-5

  • Generate knock-in models of human patient mutations

• Functional assays:

  • Hedgehog signaling assays using SAG (Smoothened agonist) stimulation

  • Cilia length and morphology analysis

  • Minigene splicing assays focusing on U12 intron-containing genes

What is the relationship between SCNM1 variants and sodium channelopathies, and how can this be investigated experimentally?

The relationship between SCNM1 variants and sodium channelopathies stems from SCNM1's role in splicing specific transcripts, particularly those of voltage-gated sodium channels.

Established Relationship:

• SCNM1 was originally identified as a modifier of a disorder caused by mutation in the sodium channel gene Scn8a in mice

• The C57BL/6J mouse strain carries the SCNM1^R187X variant, which is defective in splicing the mutated donor site in the Scn8a^medJ transcript

• This results in more severe phenotypes of the sodium channelopathy in this strain

Experimental Investigation Approaches:

• Genetic Modifier Studies:

  • Cross Scnm1 variant mice with sodium channelopathy models

  • Assess phenotypic severity across different genetic backgrounds

  • Quantify correlation between SCNM1 function and disease manifestation

• Splicing Analysis:

  • Use RT-PCR to analyze sodium channel transcript splicing in tissues from mice with different Scnm1 alleles

  • Perform minigene assays with wild-type and mutant sodium channel splice sites

  • Compare splicing efficiency between wild-type SCNM1 and variant forms

• Functional Electrophysiology:

  • Record sodium currents in neurons from mice with different Scnm1 alleles

  • Assess channel function using patch-clamp techniques in heterologous expression systems

  • Correlate splicing defects with channel dysfunction

• Human Genetic Studies:

  • Screen for SCNM1 variants in patients with unexplained sodium channelopathies

  • Perform association studies looking for SCNM1 variants that modify disease severity

  • Analyze genotype-phenotype correlations in families with sodium channel mutations

• Therapeutic Testing:

  • Test splice-modulating compounds in cells expressing SCNM1 variants

  • Evaluate viral delivery of wild-type SCNM1 in mouse models

  • Explore antisense oligonucleotides to correct specific splicing defects

• Comparative Interspecies Analysis:

  • Compare SCNM1 sequence and function across species with different susceptibilities to channelopathies

  • Evaluate evolutionary conservation of SCNM1-mediated splicing of sodium channel transcripts

What are the optimal protocols for using SCNM1 antibodies in immunofluorescence to visualize nuclear speckles?

Optimized Immunofluorescence Protocol for SCNM1 Nuclear Speckle Visualization:

Cell Preparation:

• Grow cells on poly-L-lysine coated coverslips to 70-80% confluence

• For primary cells, use low passage fibroblasts (<10 passages) to maintain native expression patterns

Fixation & Permeabilization:

• Wash cells twice with PBS at room temperature

• Fix with 4% paraformaldehyde for 10 minutes at room temperature

• Wash 3× with PBS, 5 minutes each

• Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes at room temperature

• Wash 3× with PBS, 5 minutes each

Blocking & Antibody Incubation:

• Block with 5% normal serum (matching secondary antibody host) in PBS for 1 hour at room temperature

• Incubate with primary SCNM1 antibody at 1:100-1:500 dilution in blocking buffer overnight at 4°C

• Wash 3× with PBS, 5 minutes each

• Incubate with fluorophore-conjugated secondary antibody (1:500-1:1000) for 1 hour at room temperature in the dark

• Wash 3× with PBS, 5 minutes each

Co-staining for Nuclear Speckles:

• Include antibodies against U1-70K (1:200) as a known nuclear speckle marker that colocalizes with SCNM1

• For triple staining, add antibodies against LUC7L2 (1:200) which also interacts with SCNM1

• Use different fluorophore-conjugated secondary antibodies for each primary antibody

Nuclear Counterstaining & Mounting:

• Counterstain with DAPI (1:1000 in PBS) for 5 minutes

• Wash briefly with PBS

• Mount using anti-fade mounting medium

• Seal edges with nail polish and store at 4°C in the dark

Image Acquisition & Analysis:

• Use confocal microscopy with appropriate laser lines

• Capture Z-stacks to fully visualize nuclear speckle distribution

• Perform colocalization analysis using specialized software (e.g., ImageJ with Coloc2 plugin)

• Quantify nuclear speckle number, size, and intensity across different conditions

Critical Controls:

• Include SCNM1 knockout/knockdown cells as negative controls

• Use peptide competition to confirm antibody specificity

• Include single-stained samples for fluorophore bleed-through correction

How should researchers troubleshoot non-specific binding when using SCNM1 antibodies in Western blotting?

Comprehensive Troubleshooting Guide for SCNM1 Antibody Western Blotting:

Antibody Validation Phase

• Confirm target molecular weight:

  • SCNM1 has a calculated molecular weight of approximately 26 kDa

  • Check for post-translational modifications that may alter migration

  • Verify using positive control lysates from tissues/cells known to express SCNM1

• Test multiple antibodies:

  • Compare polyclonal vs. monoclonal antibodies targeting different epitopes

  • Validate with knockout/knockdown controls if available

  • Consider testing antibodies from different vendors

Sample Preparation Optimization

• Lysis buffer selection:

  • Use RIPA buffer for nuclear proteins (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0)

  • Add fresh protease inhibitors to prevent degradation

  • Include phosphatase inhibitors if post-translational modifications are relevant

• Nuclear extraction:

  • For cleaner detection, separate nuclear and cytoplasmic fractions

  • Verify fractionation success with markers (e.g., Lamin B for nuclear fraction)

  • Consider sonication to shear chromatin and release nuclear proteins

• Protein quantification and loading:

  • Ensure equal loading (15-30 μg total protein per lane)

  • Include loading controls appropriate for nuclear proteins (e.g., Histone H3)

Western Blot Protocol Refinement

• Gel percentage optimization:

  • Use 12-15% SDS-PAGE for better resolution of small proteins like SCNM1

  • Consider gradient gels (4-20%) for simultaneous detection of multiple proteins

• Transfer conditions:

  • Optimize transfer time for small proteins (30-45 minutes)

  • Use PVDF membrane (0.2 μm pore size) for better retention of small proteins

  • Consider semi-dry transfer systems for efficient transfer of small proteins

• Blocking optimization:

  • Test alternative blocking agents (5% non-fat milk vs. 5% BSA)

  • Reduce blocking time if signal is weak (30-60 minutes)

  • Consider specialized blocking buffers for phospho-proteins if relevant

• Antibody incubation:

  • Titrate primary antibody concentration (try 1:500-1:1000)

  • Test different incubation times and temperatures (overnight at 4°C vs. 2 hours at room temperature)

  • Ensure sufficient washing between antibody incubations (3-5 washes, 5-10 minutes each)

• Detection system:

  • For weak signals, use enhanced chemiluminescence (ECL) plus or super-signal reagents

  • Consider HRP-conjugated secondary antibodies for stronger signal

  • Optimize exposure times for digital imaging systems

Non-specific Binding Resolution

• High background:

  • Increase washing stringency (add 0.1-0.5% Tween-20)

  • Reduce primary and secondary antibody concentrations

  • Pre-adsorb antibody with cell/tissue lysate from species of origin

• Multiple bands:

  • Check for known isoforms or splice variants of SCNM1

  • Test antibody on lysates from SCNM1 knockout cells

  • Perform peptide competition assay to identify specific bands

• Unexpected band sizes:

  • Consider post-translational modifications (phosphorylation, ubiquitination)

  • Check for proteolytic degradation (add more protease inhibitors)

  • Verify running conditions (reducing vs. non-reducing)

What are the best practices for analyzing SCNM1-related splicing changes using RNA-seq data?

Best Practices for Analyzing SCNM1-Related Splicing Changes in RNA-seq Data:

Experimental Design Considerations

• Sample preparation:

  • Compare wild-type vs. SCNM1-deficient samples (knockout, knockdown, or patient-derived)

  • Include SCNM1 rescue conditions to confirm specificity of observed changes

  • Consider time-course experiments to capture dynamic splicing events

• Sequencing parameters:

  • Use paired-end sequencing (minimum 100-150 bp reads) for better splice junction detection

  • Aim for ≥50 million reads per sample for adequate detection of minor intron splicing events

  • Ensure sufficient sequencing depth for detecting low-abundance transcripts

• Controls and replicates:

  • Include at least 3-4 biological replicates per condition

  • Consider technical replicates for validation of rare splicing events

  • Include samples with known splicing alterations as positive controls

Data Processing Pipeline

• Quality control and preprocessing:

  • Assess read quality with FastQC

  • Trim adapters and low-quality bases using Trimmomatic or similar tools

  • Filter out rRNA reads if not depleted during library preparation

• Alignment strategy:

  • Use splice-aware aligners (STAR, HISAT2) with optimized parameters for novel junction detection

  • Create a custom annotation file including known U12-type introns

  • Consider genome-guided transcriptome assembly to identify novel transcripts

• Splicing-specific analyses:

  • Apply specialized tools for alternative splicing detection:

    • rMATS or MAJIQ for differential splicing analysis

    • LeafCutter for de novo splicing analysis

    • SplAdder for splice graph augmentation and analysis

  • Focus particularly on U12-type introns, which are processed by the minor spliceosome

Data Analysis Focus Areas

• U12 intron splicing efficiency:

  • Calculate intron retention ratio for U12-type introns

  • Compare with U2-type introns as internal controls

  • Identify global patterns of U12 intron retention

• Specific SCNM1 targets:

  • Analyze previously identified SCNM1 targets such as TMEM107, FAM92A, DERL2, ZC3H8, and C17orf75

  • Look for genes containing weak or non-consensus splice sites

  • Focus on sodium channel genes, particularly Scn8a

• Alternative splicing patterns:

  • Quantify different types of splicing events (exon skipping, alternative 5'/3' splice sites, mutually exclusive exons)

  • Calculate percent spliced in (PSI) values for alternative exons

  • Identify cryptic splice site activation

• Pathway enrichment analysis:

  • Perform Gene Ontology analysis on differentially spliced genes

  • Look for enrichment of cilia-related pathways

  • Analyze enrichment of Hedgehog signaling components

Validation and Integration Strategies

• Experimental validation:

  • Confirm key splicing changes by RT-PCR

  • Use minigene assays to validate direct SCNM1 targets

  • Correlate splicing changes with protein expression where possible

• Integration with other data types:

  • Correlate splicing changes with phenotypic data

  • Integrate with protein-protein interaction data for SCNM1

  • Combine with CLIP-seq or RNA-IP data if available to identify direct binding targets

• Visualization and reporting:

  • Create sashimi plots for key splicing events

  • Develop heatmaps clustering similar splicing patterns

  • Report percent spliced in (PSI) values with confidence intervals

Special Considerations for SCNM1 Research

• Focus on non-consensus splice sites that may be particularly dependent on SCNM1 function

• Compare results with known SCNM1 variant effects (e.g., C57BL/6J variant)

• Evaluate tissue-specific effects, as SCNM1-dependent splicing may vary across cell types

• Consider compensatory mechanisms that may mask some SCNM1-dependent splicing events

How might SCNM1 antibodies be used in developing therapeutic approaches for splicing-related disorders?

SCNM1 antibodies could play crucial roles in developing therapeutic approaches for splicing-related disorders through multiple research pathways:

Diagnostic Applications:

• Use SCNM1 antibodies to develop immunoassays for detecting functional SCNM1 deficiency in patient samples

• Develop tissue staining protocols to identify abnormal SCNM1 localization or expression in biopsies

• Create companion diagnostics to identify patients likely to respond to splicing modulators

Target Validation and Screening:

• Employ SCNM1 antibodies in high-throughput screening assays to identify compounds that stabilize SCNM1-spliceosome interactions

• Develop cellular assays with fluorescently tagged SCNM1 antibodies to monitor real-time splicing activity

• Use immunoprecipitation with SCNM1 antibodies to validate direct targets for antisense oligonucleotide therapy

Therapeutic Development:

• Small molecule screening:

  • Use SCNM1 antibodies in displacement assays to identify molecules that mimic SCNM1 function

  • Develop assays to screen for compounds that stabilize mutant SCNM1 protein

  • Validate compound effects on SCNM1-dependent splicing using minigene assays

• Gene therapy approaches:

  • Use SCNM1 antibodies to confirm successful viral delivery of functional SCNM1

  • Develop immunohistochemistry protocols to verify expression in target tissues

  • Monitor restoration of proper splicing complex formation in treated cells

• Antisense oligonucleotide therapy:

  • Identify critical SCNM1-dependent splicing events as targets for antisense therapy

  • Use SCNM1 antibodies to validate that ASOs restore proper spliceosome assembly

  • Focus on U12 intron-containing genes affected in orofaciodigital syndrome

Monitoring Therapeutic Response:

• Develop tissue and blood-based assays using SCNM1 antibodies to monitor treatment efficacy

• Use immunofluorescence to assess normalization of nuclear speckle patterns following therapy

• Combine with splicing assays to correlate SCNM1 function with clinical improvement

Combinatorial Approaches:

• Pair SCNM1-targeted therapies with other splicing modulators for synergistic effects

• Develop dual-targeting strategies addressing both SCNM1 and its interaction partners like LUC7L2

• Create modular therapeutic approaches tailored to specific splicing defects in individual patients

What are the latest methods for studying the interactions between SCNM1 and the minor spliceosome components?

The study of interactions between SCNM1 and minor spliceosome components has advanced significantly, with several cutting-edge methodologies now available:

Advanced Protein-Protein Interaction Methods

• Proximity-Dependent Biotin Labeling (BioID/TurboID):

  • Fuse SCNM1 to biotin ligase (BioID2 or TurboID)

  • Express in relevant cell types and add biotin

  • Identify proximal proteins by streptavidin pulldown followed by mass spectrometry

  • Advantage: Captures weak and transient interactions in native cellular context

• CRISPR-Based Tagging Strategies:

  • Edit endogenous SCNM1 to include Split-GFP, HaloTag, or SNAP-tag

  • Perform live-cell imaging to track SCNM1 dynamics within nuclear speckles

  • Combine with fluorescently tagged minor spliceosome components

  • Advantage: Observes physiological interactions without overexpression artifacts

• Quantitative Interaction Proteomics:

  • Use SILAC or TMT labeling with SCNM1 immunoprecipitation

  • Compare interaction profiles between wild-type and disease-associated SCNM1 variants

  • Apply computational modeling to construct interaction networks

  • Advantage: Provides quantitative assessment of interaction strengths

RNA-Protein Interaction Methods

• Enhanced CLIP-seq Approaches:

  • irCLIP or eCLIP with SCNM1 antibodies to map direct RNA binding sites

  • Focus analysis on U12-type introns and their flanking sequences

  • Correlate binding patterns with splicing outcomes

  • Advantage: Single-nucleotide resolution of RNA-protein interactions

• RNA-Protein Interaction Detection (RaPID):

  • Tag specific U12 snRNAs with MS2 hairpins

  • Purify complexes and identify associated proteins including SCNM1

  • Analyze dynamics of complex assembly and disassembly

  • Advantage: Allows study of specific RNA targets in living cells

• Structure Determination Technologies:

  • Cryo-EM of minor spliceosome complexes including SCNM1

  • Crosslinking Mass Spectrometry (XL-MS) to map interaction interfaces

  • Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) to identify conformational changes

  • Advantage: Provides structural basis for understanding function

Functional Splicing Analysis Methods

• In vitro Splicing Assays with Recombinant Components:

  • Reconstitute minor spliceosome with purified components

  • Add or deplete SCNM1 to assess direct functional impact

  • Monitor splicing kinetics with fluorescent reporters

  • Advantage: Controlled system to dissect specific mechanistic steps

• Single-Molecule Splicing Visualization:

  • Label spliceosome components with orthogonal fluorophores

  • Perform single-molecule FRET experiments to track conformational changes

  • Observe real-time assembly and catalysis events

  • Advantage: Reveals dynamic processes obscured in bulk experiments

• Genome-Wide Minor Intron Splicing Analysis:

  • Apply tailored bioinformatic pipelines to specifically track U12 intron splicing

  • Compare cell lines with SCNM1 variants or targeted modifications

  • Correlate with minor spliceosome component levels and modifications

  • Advantage: Comprehensive view of SCNM1's global impact on minor splicing

Emerging Technologies

• Liquid-Liquid Phase Separation (LLPS) Analysis:

  • Study SCNM1's role in nuclear speckle formation through LLPS

  • Assess how disease mutations affect condensate properties

  • Examine dynamics and material properties of splicing bodies

  • Advantage: Connects molecular interactions to higher-order cellular organization

• Time-Resolved Proteomics:

  • Apply pulse-SILAC or SNAPL approaches to track protein turnover

  • Analyze assembly kinetics of minor spliceosome complexes

  • Monitor SCNM1 incorporation into functional spliceosomes

  • Advantage: Reveals temporal dimension of complex assembly

• Integrative Multi-omics Approaches:

  • Combine RNA-seq, proteomics, and interaction data

  • Develop computational models of SCNM1-dependent splicing regulation

  • Apply machine learning to predict splicing outcomes based on sequence features

  • Advantage: Holistic understanding of SCNM1's role in the splicing process